In search of a molecular diagnosis for a child with bilateral vestibular schwannomas, a family undergoes a diagnostic odyssey ...

NEW YORK – BioNTech and Roche subsidiary Genentech are discontinuing testing of their jointly developed personalized cancer vaccine in colorectal cancer patients. The companies were testing the mRNA ...

The company said it will use the funds raised from sales of convertible notes to fund its oncology business, including intismeran autogene.

The hospital, which has been making investments into precision medicine, inked a multi-phase deal to integrate PGx into clinical workflows.

Sangrail Biologics is already discussing with the FDA a regulatory path for the gene therapy that Abeona Therapeutics dropped ...

Regulators approved the FGFR1/2/3 inhibitor based on data showing a 42.5 percent objective response rate and 16.6 months of median overall survival.

University of Toronto researchers are betting yes, pointing to tRNA's ease of administration and efficacy advantages over ...

The therapy binds to CD3 receptors on T cells, activating them and directing them past the blood-brain barrier to tumors.

For patients with microsatellite instability of mismatch repair deficiency, the final decision cements access to the drug, which was previously offered provisionally.

The firm is testing the next dose level of RV-01 in a Phase I/IIa study after clearance from a safety and monitoring committee.

NEW YORK – The US Food and Drug Administration on Wednesday approved Revolution Medicines' pan-RAS inhibitor Rasonque (daraxonrasib) as a second-line treatment for all-comer patients with metastatic ...